Purdue Institute for Cancer Research

For the fourth year in a row, Purdue is a top 10 U.S. public university in the 2027 !

This achievement reflects our long-standing dedication to world-class research and educational excellence.

⛳️ Join the National Football Foundation Joe Tiller Chapter for the Tyler Trent Golf Outing on Friday, Sept. 4, at Coyote Crossing Golf Club in West Lafayette.

🎗️ A portion of the proceeds will support the Tyler Trent Endowment at the Purdue Institute for Cancer Research.

🎟️ Golfers who register by Aug. 28 will be entered into a drawing for a pair of football tickets to Purdue’s game against Indiana State.

Learn more and register: purdue.link/T2-golf-26

Knowledge is power against cancer.

Ours has been building for decades.

At the Purdue Institute for Cancer Research, federally funded discovery turns deeper understanding of disease into new possibilities for prevention, detection and treatment, improving lives today and for generations to come.

There is a thread connecting generations of American progress: it is the belief that there is always something more to learn. A better future waiting to be discovered. And the determination to pursue it.

Happy Independence Day, Boilermakers!

This week, President Emeritus Mitch Daniels began serving as Purdue's interim president. Please join the Boilermaker community in welcoming back President Daniels.

Purdue's research enterprise grew remarkably during President Daniels' years of leadership and service to the university. We look forward to building on that momentum together by translating foundational science into new knowledge, technologies and advances that shape the future of cancer research.

https://www.purdue.edu/president/interim/

Where world-class research becomes real-world impact.

# 1️⃣ public university in Indiana, according to 's 2026 Best Colleges rankings.

Purdue's continued recognition among the nation's top public universities underscores the excellence that fuels discoveries at the Purdue Institute for Cancer Research, from understanding how cancer begins to advancing the medicines and technologies that move us closer to its defeat.

Purdue researchers, including Nicolás Morato and R. Graham Cooks, have developed a next-generation platform that integrates chemical synthesis, biological testing, and mass spectrometry into a single automated workflow, accelerating early-stage drug discovery, including the search for new cancer therapies.

Published in PNAS, the work reflects more than a decade of development built on Purdue's pioneering DESI-MS technology. The project was supported by The National Institutes of Health (NIH)'s National Center for Advancing Translational Sciences (NCATS) through its ASPIRE program.

🗞️ Read the full story: purdue.link/nextgen-cancer-tech
🔬 Explore the research: purdue.link/DESI.MS-drug.PNAS.26

| Purdue Science | Purdue Innovates

Cancer's most dangerous behaviors, including immune evasion, therapy resistance and metastasis, can arise not only from mutations in DNA itself, but also from disruptions in the system that controls gene expression.

Purdue University researcher Emily Dykhuizen studies chromatin regulation, the molecular machinery that determines which genes are accessible in a cell. When chromatin regulators are misregulated, genes that should remain silenced can be switched on, enabling cancer cells to take on new functions and identities.

In a collaboration with fellow Purdue Institute for Cancer Research member Michael Wendt, Dykhuizen is investigating why breast cancer cells lose their ability to metastasize to the lungs when a chromatin remodeling gene is silenced. Researchers suspect the change may restore an immune response that had previously been suppressed.

Read the story to learn more 🗞️ https://purdue.link/ED-cancer-machinery

Purdue Institute for Cancer Research member David Thompson co-led new research with collaborators at Indiana University School of Medicine that advances a nanoparticle delivery strategy for targeted therapies in multiple myeloma.

Using lipid nanoparticles, researchers improved targeting of multiple myeloma cells in the bone marrow while reducing delivery to unintended locations.

Thompson is a professor of chemistry in Purdue Science.

Read more about the findings below.
Read the paper ➡️ purdue.link/nanopub.26.DT

Cancer treatments can harm healthy cells along with cancer cells, leading to difficult side effects.

New research co-led by IU School of Medicine scientists could help change that. Researchers developed a nanoparticle delivery system that targets multiple myeloma cells while avoiding healthy cells, a promising step toward safer and more effective blood cancer treatments.